



Supporting Information for: *Withania Somnifera* Root Extract Enhances Chemotherapy Through ‘Priming’

A MDA-MB231




MDA-MB231						
10	0	-15.84	-8.95	-9.12	SYNERGY PLOT	
5	0	-12.35	-9.56	-5.51	SYNERGY	0
1	0	-12.77	-16.43	-5.06	95% CI	NS
0	0	0	0	0	ANTAGONISM	-95.59
0	50	100	150	95% CI		-2 - -189

B HT-29



HT-29						
10	0	-24.28	2.77	-14.16	SYNERGY PLOT	
5	0	-24.48	-1.91	-7.11	SYNERGY	5.09
1	0	-17.6	2.32	-4.07	95% CI	NS
0	0	0	0	0	ANTAGONISM	-93.61
0	50	100	150	95% CI		0 - -187

C MCF10A



MCF10A						
10	0	-26.83	-19.1	-2.21	SYNERGY PLOT	
5	0	-16.78	-6.23	-0.97	SYNERGY	0
1	0	-13.21	-7.02	-0.65	95% CI	NS
0	0	0	0	0	ANTAGONISM	-93
0	50	100	150	95% CI		-13 - -173

Figure S3. Evaluating the drug-drug interactions upon combining treatments of *W. somnifera* and cisplatin.

The interactions of *W. somnifera* and cisplatin was assessed by the methods described in Prichard and Shipman (29). Cell viability was examined following treatment with *W. somnifera* root extract (0 µg/mL -10 µg/mL) in combination with cisplatin (0 µM -150 µM). **(A)** MDA-MB231, **(B)** HT-29 **(C)** MCF10A 3D models and data table sets represent the antagonist effect of the drug-drug interactions. Data represents the average of 5 independent experiments.